MedPath

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

Not Applicable
Completed
Conditions
Prostate Adenocarcinoma
Registration Number
NCT03496844
Lead Sponsor
University of Arizona
Brief Summary

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
15
Inclusion Criteria
  1. Male
  2. Be ≥ 18 years of age
  3. Diagnosed with prostate cancer
  4. Be willing and able to provide informed consent
  5. Be informed of the investigational nature of this study
Exclusion Criteria
  1. Having a history of severe claustrophobia
  2. Weight exceeding 400lbs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy1 year

True positive and false positive rates of positive findings in the skeleton on F-18 fluciclovine-PET/CT scan compared to gold standard pathology from bone biopsy

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Arizona

🇺🇸

Tucson, Arizona, United States

University of Arizona
🇺🇸Tucson, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.